REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Core Points - Rosen Law Firm is reminding purchasers of Replimune Group, Inc. securities about a class action lawsuit with a lead plaintiff deadline of September 22, 2025 [1][3] - Investors who purchased Replimune securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Case Details - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate and not well-controlled [5] - As a result of these misleading statements, investors suffered damages when the true details were revealed [5] Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6] - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7] Rosen Law Firm's Credentials - The firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4]